JUVÉDERM®

JUVÉDERM® VOLUMA® XC Important Safety Information: Download link
JUVÉDERM® VOLUX® XC Important Safety Information: Download link
JUVÉDERM® VOLLURE® XC Important Safety Information: Download link
JUVÉDERM® VOLBELLA® XC Important Safety Information: Download link
JUVÉDERM® Ultra Plus XC Important Safety Information: Download link
JUVÉDERM® Ultra XC Important Safety Information: Download link

THE JUVÉDERM® COLLECTION OF FILLERS

 

SPECIFICALLY DESIGNED TO MEET YOUR PATIENTS’ NEEDS

A diverse range of products for a variety of aesthetic goals.

Order Now

Compare Report Abuse

THE JUVÉDERM® COLLECTION IS

SPECIFICALLY
DESIGNED

TO MEET YOUR PATIENTS’ NEEDS

Each product in the JUVÉDERM® Collection is specifically designed,
so you can customize treatment for your patients’ aesthetic goals.


THE JUVÉDERM® COLLECTION OF FILLERS

SPECIFICALLY DESIGNED TO MEET YOUR PATIENTS’ NEEDS

A diverse range of products for a variety of aesthetic goals.


1 CHOSEN DERMAL FILLER COLLECTION

THE JUVÉDERM® COLLECTION IS #1 WORLDWIDE FOR A REASON

JUVEDERM VOLLURE XC


THE TAILORED GEL PROPERTIES IN JUVÉDERM® PRODUCTS WORK TOGETHER
TO CREATE SMOOTH, UNIQUELY DESIGNED FILLERS*

FIRMNESS

COHESIVITY

WATER AFFINITY

HA CONCENTRATION

*Gel properties assessed in vitro. Clinical significance has not been established.


THE JUVÉDERM® ERGONOMIC SYRINGE FIT AND
FEEL IS DESIGNED FOR YOUR COMFORT.
JUVÉDERM® COLLECTION OF FILLERS SYRINGE

United States ergonomics certified.

The JUVÉDERM® Collection of Fillers is the only collection of fillers that uses a certified ergonomic syringe designed for comfort to improve your injecting experience.Each syringe design is color-coded by product for easy differentiation.


THE JUVÉDERM® ERGONOMIC SYRINGE IS DESIGNED
TO MINIMIZE FATIGUE IN KEY AREAS

COLOR-CODED FOR EASY PRODUCT DIFFERENTIATION

T R E A T M E N T    A R E A S

MIDFACE

DESIGNED TO VOLUMIZE FOR LIFT
JUVÉDERM® VOLUMA® XC IS SPECIFICALLY DESIGNED TO BE A FIRM, STRUCTURAL GEL.

JUVÉDERM® VOLUMA® XC is a structural gel for adding volume to lift and contour.

The G’ and cohesivity of JUVÉDERM® VOLUMA® XC work together to
contribute to lift capacity. G’/firmness alone is not a predictor of lift capacity.

JUVÉDERM® VOLUMA® XC provides natural-looking and lasting results in thecheeks that last up to 2 years with optimal treatment.


CHIN

DESIGNED TO DEFINE
JUVÉDERM® VOLUMA® XC IS A STRUCTURAL GELFOR ADDING VOLUME AND CONTOUR


JUVÉDERM® VOLUMA® XC MOLDABILITY AT INITIAL INJECTION
Moldability

Derived from preclinical studies evaluating gel properties.Clinical significance has not been established.

 


JAWLINE

DESIGNED TO DEFINE
HELP YOUR PATIENTS LOVE THEIR LOOK FROM EVERY ANGLE
WITH JUVÉDERM® VOLUX® XC
  • The first and only HA filler for jawline definition 
  • A defining gel specifically designed for the jawline
  • High patient satisfaction and proven results 


JUVÉDERM® VOLUX® XC HAS THE HIGHEST G’
AND COHESIVITY IN THE VYCROSS® RANGE,
MAKING IT IDEAL FOR DEFINING THE JAWLINE

 


LINES

DESIGNED TO LAST*
THE #1 CHOSEN DERMAL FILLER COLLECTION FOR
MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS.

The images above depict tissue integration of JUVÉDERM® Ultra Plus XC andJUVÉDERM® VOLLURE® XC in animal models. The filler gel, in blue, integratesinto the surrounding collagenous dermis tissue, in red.

JUVÉDERM® ULTRA PLUS XC AND JUVÉDERM® VOLLURE® XC
ARE THE LONGEST-LASTING DERMAL FILLERS FDA APPROVED FOR MODERATETO SEVERE FACIAL WRINKLES AND FOLDS.
  • JUVÉDERM® Ultra Plus XC lasts beyond 1 year3†
  • JUVÉDERM® VOLLURE® XC lasts through 18 months6†

LIPS

DESIGNED FOR DIVERSE LIP NEEDS*

Different HA concentrations contribute to:
Subtle volume with JUVÉDERM® VOLBELLA® XC
plump with JUVÉDERM® Ultra XC

Different HA concentrations contribute to:
Subtle volume with JUVÉDERM® VOLBELLA® XC
plump with JUVÉDERM® Ultra XC

Comparison showing how different HA concentrations contribute to volume between JUVEDERM® ULTRA XC (15 mg/ml) and JUVEDERM® VOLBELLA® XC (24 mg/ml).


UNDEREYES

DESIGNED FOR SMOOTH AND SUBTLE VOLUME
JUVÉDERM® VOLBELLA® XC IS A SOFT GEL FOR SUBTLE VOLUME.

The eye area is a top concern for patients,* and subtle volume isappropriate for treating the delicate infraorbital hollows area. JUVÉDERM®VOLBELLA® XC has moderate G’, low water affinity, and low cohesivity,making it a suitable product for the treatment of undereye hollows.


IMPORTANT SAFETY INFORMATION

JUVÉDERM® Collection of Fillers INDICATIONS AND IMPORTANT SAFETY INFORMATION

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.

JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.

JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

WARNINGS
  • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
PRECAUTIONS
  • To minimize the risk of potential complications, these products should only be used by healthcare professionals who are knowledgeable about the anatomy and the product(s) for use in indicated area(s), and who have appropriate training in facial anatomy, vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
  • The potential risks of soft tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
  • The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
  • The safety for use of these products in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
  • The safety for use during pregnancy and in breastfeeding females has not been established
  • The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation and in patients between 22 and 80 years of age for chin augmentation
  • The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and the safety for use of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC, and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
  • Dermal filler implantation carries a risk of infection. Follow standard precautions
  • Dermal fillers should be used with caution in patients on immunosuppressive therapy
  • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
  • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
  • The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
  • The safety for use of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
  • JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
  • Patients may experience late-onset adverse events with injectable gel implants, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
  • Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lb) body mass per year. The safety of injecting greater amounts has not been established
  • Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied
ADVERSE EVENTS

The most common reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support at 1-877-345-5372. Please visit JuvedermDFU.com for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-voluma-xc_dfu.pdf for JUVÉDERM® VOLUMA® XC

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volux-xc_dfu.pdf for JUVÉDERM® VOLUX® XC

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-vollure-xc_dfu.pdf for JUVÉDERM® VOLLURE® XC

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volbella_dfu.pdf for JUVÉDERM® VOLBELLA® XC

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf for JUVÉDERM® Ultra Plus XC

Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-xc_dfu.pdf for JUVÉDERM® Ultra XC

Product Enquiry

Please Login to make enquiry about this product

Main Menu